Immunex Corporation

Leland Stanford Junior University

Amgen Inc.

Adaptive Biotechnologies Corporation

Imdaptive, Inc.

Viral Logic Systems Technology Corp.

Steven R Wiley

Raymond G Goodwin

Randal Robert Ketchem

William C Fanslow, Iii

Robert F DuBose

Kristine M Kim

Craig A Smith

Ajamete Kaykas

Howard R G Clarke

Peter Probst

Adel Youakim

Methods are provided for producing monoclonal antibody candidates using adaptive immunity profiling. In some aspects, the method provides for the use of massively parallel signature sequencing.

Adaptive immunity profiling and methods for generation of monoclonal antibodies

The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.

Tweak receptor

Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.

CD47 related compositions and methods for treating immunological diseases and disorders

The present invention provides methods for identifying viral virulence factors and for identifying cellular polypeptides to which the viral polypeptides bind. The cellular polypeptide is useful as a therapeutic target or as a therapeutic agent for treating diseases and disorders, including immunological diseases or disorders.

Methods for identifying polypeptide targets and uses thereof for treating immunological diseases

A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.

DNA encoding a soluble fragment of TRAIL polypeptide

TWEAK receptor

Use of TRAIL polypeptides to induce apoptosis

The present invention provides methods and compositions relating to fusion proteins comprising multimeric soluble TWEAK receptor fragments and an oligomerization domain. Such fusion proteins are useful for antagonizing the TWEAK receptor and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and inflammatory conditions.

Compositions and methods relating to multimeric and oligomeric soluble fragments of the TWEAK receptor

Growing community of inventors

Seattle, WA, United States of America

Steven R Wiley